Ibritumomab tiuxetan for non-Hodgkin’s lymphoma
Author:
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
http://www.tandfonline.com/doi/pdf/10.1586/14737140.6.6.861
Reference37 articles.
1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
2. Ongoing Trials with Yttrium 90–Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma
3. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunotherapeutics: Advancing precision medicine in cancer treatment;IP International Journal of Comprehensive and Advanced Pharmacology;2024-03-15
2. Omics Applications in Cancer Immunology;Handbook of Cancer and Immunology;2024
3. Special Issue: Evaluation of the Antitumor Mechanism of Armed Antibodies;Pharmaceuticals;2023-12-05
4. Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study;Cancers;2022-01-27
5. Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit;Oncologic Critical Care;2019-10-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3